By integrating cell-specific genetic labeling, pharmacological and genetic PKM2 suppression, and advanced protein interaction analyses, this study reveals new insights into the interplay between metabolic regulation and transcriptional control in CKD and provides a basis for targeted antifibrotic therapy. The gene discussed is PKM; the disease is chronic kidney disease.